Sihuan Given SFDA Approval to Start Clinical Trial of Innovative Antibiotic
Sihuan Pharma received approval from the SFDA to begin clinical trials of the company’s new antibiotic, benapenem, a Category 1.1 drug that is a member of the carbapenem class of antibiotics. Both the APIs and injection form of the drug are patented. Sihuan said the antibiotic will begin its clinical trial in the first half of 2013, the company’s third Category 1 innovative drug to enter human trials. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here